Antisense Therapeutics — executive interview with James Garner, chief executive officer

Antisense Therapeutics — executive interview with James Garner, chief executive officer

Antisense Therapeutics — 1 video in collection

More on this equity

Antisense Therapeutics is an Australian biotechnology company developing antisense oligonucleotide therapies for treating rare diseases. Its lead asset, ATL1102, is being investigated as a targeted anti-inflammatory therapy to treat Duchenne muscular dystrophy. In a positive strategic pivot, the trial design was amended to a smaller Phase IIb study (n=42 vs 108) that should provide a nearer-term catalyst, if positive readouts are achieved.

In this video, James Garner, chief executive officer, explains the company’s background and gives an overview of its clinical pipeline.


You may also be interested in these:

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free